Department of Otorhinolaryngology, University Medical Center, Albert-Ludwigs-University, Freiburg, Germany.
Clinics (Sao Paulo). 2012;67 Suppl 1(Suppl 1):19-28. doi: 10.6061/clinics/2012(sup01)05.
Head and neck paragangliomas are tumors arising from specialized neural crest cells. Prominent locations are the carotid body along with the vagal, jugular, and tympanic glomus. Head and neck paragangliomas are slowly growing tumors, with some carotid body tumors being reported to exist for many years as a painless lateral mass on the neck. Symptoms depend on the specific locations. In contrast to paraganglial tumors of the adrenals, abdomen and thorax, head and neck paragangliomas seldom release catecholamines and are hence rarely vasoactive. Petrous bone, jugular, and tympanic head and neck paragangliomas may cause hearing loss. The internationally accepted clinical classifications for carotid body tumors are based on the Shamblin Class I-III stages, which correspond to postoperative permanent side effects. For petrous-bone paragangliomas in the head and neck, the Fisch classification is used. Regarding the molecular genetics, head and neck paragangliomas have been associated with nine susceptibility genes: NF1, RET, VHL, SDHA, SDHB, SDHC, SDHD, SDHAF2 (SDH5), and TMEM127. Hereditary HNPs are mostly caused by mutations of the SDHD gene, but SDHB and SDHC mutations are not uncommon in such patients. Head and neck paragangliomas are rarely associated with mutations of VHL, RET, or NF1. The research on SDHA, SDHAF2 and TMEM127 is ongoing. Multiple head and neck paragangliomas are common in patients with SDHD mutations, while malignant head and neck paraganglioma is mostly seen in patients with SDHB mutations. The treatment of choice is surgical resection. Good postoperative results can be expected in carotid body tumors of Shamblin Class I and II, whereas operations on other carotid body tumors and other head and neck paragangliomas frequently result in deficits of the cranial nerves adjacent to the tumors. Slow growth and the tendency of hereditary head and neck paragangliomas to be multifocal may justify less aggressive treatment strategies.
头颈部副神经节瘤是起源于特殊神经嵴细胞的肿瘤。主要部位是颈动脉体以及迷走神经、颈静脉和鼓室副神经节。头颈部副神经节瘤是生长缓慢的肿瘤,有些颈动脉体瘤在颈部形成无痛性侧块已有多年。症状取决于具体位置。与肾上腺、腹部和胸部的副神经节瘤不同,头颈部副神经节瘤很少释放儿茶酚胺,因此很少有血管活性。岩骨、颈静脉和鼓室头颈部副神经节瘤可导致听力损失。颈动脉体瘤的国际公认临床分类基于 Shamblin I-III 期,这与术后永久性副作用相对应。对于头颈部的岩骨副神经节瘤,使用 Fisch 分类。关于分子遗传学,头颈部副神经节瘤与九个易感性基因相关:NF1、RET、VHL、SDHA、SDHB、SDHC、SDHD、SDHAF2(SDH5)和 TMEM127。遗传性 HNPs 主要由 SDHD 基因突变引起,但此类患者中也不罕见 SDHB 和 SDHC 突变。头颈部副神经节瘤很少与 VHL、RET 或 NF1 的突变相关。对 SDHA、SDHAF2 和 TMEM127 的研究仍在进行中。SDHD 基因突变的患者中多发性头颈部副神经节瘤很常见,而 SDHB 基因突变的患者中恶性头颈部副神经节瘤更为常见。治疗选择是手术切除。Shamblin I 和 II 类颈动脉体瘤的术后效果良好,而其他颈动脉体瘤和其他头颈部副神经节瘤的手术经常导致与肿瘤相邻的颅神经缺损。遗传性头颈部副神经节瘤的生长缓慢和多灶性倾向可能证明采用不那么激进的治疗策略是合理的。